1. bookVolume 75 (2021): Issue 2 (April 2021)
Journal Details
First Published
14 Sep 2008
Publication timeframe
6 times per year
access type Open Access

Significance of Hypouricaemia in the Development of Neurodegenerative Diseases

Published Online: 08 May 2021
Page range: 92 - 98
Received: 13 Nov 2020
Accepted: 13 Jan 2021
Journal Details
First Published
14 Sep 2008
Publication timeframe
6 times per year

Hypouricaemia has received relatively little attention in the literature. As a result, there is less awareness or understanding of the potential risks of low uric acid levels. Emerging research indicates that normal uric acid levels may have an antioxidative and neuroprotective effect. This study aims to investigate possible associations between hypouricaemia and neurodegenerative disease. Data was collected from seventy-seven outpatients and inpatients who underwent routine uric acid testing, who were then stratified into patients with and without neurodegenerative disease. Patients with renal pathologies and patients using uric acid altering medications were excluded from the study. There was a significant difference in the prevalence of Alzheimer’s disease between hypouricemic and normouricemic patients (p = 0.001), however there was no difference in the prevalence of vascular dementia (p = 0.45). This study provides evidence that hypouricaemia has potential effects on health, specifically on the rate of neurodegenerative diseases such as Alzheimer’s disease and gives weight to the potential neuroprotective role of uric acid.


Ames, B. N., Cathcart, R., Schwiers, E., Hochstein P. (1981). Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: A hypothesis. Proc. Natl. Acad. Sci.,78 (11), 6858–6862.Search in Google Scholar

Bardin, T., Keenan, R.T., Khanna, P. P., Kopicko, J., Fung, M., Bhakta, N., Adler, S., Storgard, C., Baumgartner, S., So, A. (2017). Lesinurad in combination with allopurinol: A randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study). Ann. Rheum. Dis., 76 (5), 811–820.Search in Google Scholar

Becker, M. A., Schumacher, R. H., Wortmann, R. L., MacDonald, P. A., Eustace, D., Palo, W. A., Streit, J., Joseph-Ridge, N. (2005). Febuxostat compared with allopurinol in patients with hyperuricemia and gout. New Engl. J. Med.,353 (23), 2450–2461.Search in Google Scholar

Becker, B. D., Coremans, C., Chaumont, M., Delporte, C., Antwerpen, P. V., Franck, T., Rousseau, A., Boudjeltia, K. Z., Cullu, P., Borne, P. V. D. (2019). Severe hypouricemia impairs endothelium-dependent vasodilatation and reduces blood pressure in healthy young men: A randomized, placebo-controlled, and crossover study. J. Amer. Heart Assoc.,8 (23), e013130.Search in Google Scholar

Bellomo, G., Selvi, A. (2018). Uric acid: The lower the better? Contrib. Nephrol., 192, 69–76.Search in Google Scholar

Braga, T. T., Forni, M. F., Correa-Costa, M., Ramos, R. N., Barbuto, J. A., Branco, P., Castoldi A., Hiyane M. I., Davanso M. R., Latz E., Franklin B. S., Kowaltowksi A., Camara, N. O. S. (2017). Soluble uric acid activates the NLRP3 inflammasome. Sci. Rep.,7 (1), 39884.Search in Google Scholar

Bowman, G. L., Shannon, J., Frei, B., Kaye, J. A., Quinn, J. F. (2010). Uric acid as a CNS antioxidant. J. Alzheimers Dis.,19 (4), 1331–1336.Search in Google Scholar

Chen, X., Guo, X., Huang, R., Chen, Y., Zheng, Z., Shang, H. (2014). Serum uric acid levels in patients with Alzheimer’s Disease: A meta-analysis. PLOS ONE,9 (4), e94084.Search in Google Scholar

Cho, S. K., Chang, Y., Kim, I., Ryu, S. (2018). U-Shaped association between serum uric acid level and risk of mortality. Arthritis Rheumatol.,70 (7), 1122–1132.Search in Google Scholar

Dalbeth, N., Jones, G., Terkeltaub, R., Khanna, D., Kopicko, J., Bhakta, N., Adler, S., Fung, M., Storgard, C., Baumgartner, S., Perez-Ruiz, F. (2017). Lesinurad, a selective uric acid reabsorption inhibitor, in combination with Febuxostat in patients with tophaceous gout: Findings of a Phase III clinical trial. Arthritis Rheumatol.,69 (9), 1903–1913.Search in Google Scholar

Esparza Martin, N., Garcia Nieto, V. (2011). Hypouricemia and tubular transport of uric acid. Revista Nefrologia, 31, 44–50.Search in Google Scholar

Fang, P., Li, X., Luo, J.J., Wang, H., Yang, X. (2013). A double-edged sword: Uric acid and neurological disorders. Brain Disord. Ther.,2 (2), 109.Search in Google Scholar

Fujinaga, S., Ito, A., Nakagawa, M., Watanabe, T., Ohtomo, Y., Shimizu, T. (2013). Posterior reversible encephalopathy syndrome with exercise-induced acute kidney injury in renal hypouricemia type 1. Eur. J. Pediatrics, 172 (11), 1557–1560.Search in Google Scholar

Graf, S. W., Whittle, S. L., Wechalekar, M. D., Moi, J. H. Y., Barrett, C., Hill, C. L., Littlejohn, G., Lynch, N., Major, G., Taylor, A. L., Buchbinder, R., Zochling, J. (2015). Australian and New Zealand recommendations for the diagnosis and management of gout: Integrating systematic literature review and expert opinion in the 3e Initiative. Int. J. Rheum. Dis.,18 (3), 341–351.Search in Google Scholar

Hui, M., Carr, A., Cameron, S., Davenport, D., Doherty, M., Forrester, H.., Jenkins, W., Jordan, K. M., Mallen, C. D., McDonald, T. M., Nuki, G., Pywell, A., Zhang, W., Roddy, E. (2017). The British Society for Rheumatology Guideline for the Management of Gout. Rheumatology, 56 (7), e1–e20.Search in Google Scholar

Kanbay, M., Segal, M., Afsar, B., Kang, D.-H., Rodriguez-Iturbe, B., Johnson, R. J. (2013). The role of uric acid in the pathogenesis of human cardiovascular disease. Heart, 99 (11), 759–766.Search in Google Scholar

Kiltz, U., Alten, R., Fleck, M., Krüger, K., Manger, B., Müller-Ladner, U., Nuesslein, H., Reuss-Borst, M., Schwarting, A., Schulze-Koops, H., Tausche, A., Braun, J., (2017). Evidenzbasierte Empfehlung zur Diagnostik und Therapie der Gichtarthritis im fachärztlichen Sektor. Zeitschrift für Rheumatologie, 76 (2), 118–124 (in German).Search in Google Scholar

Kocahan, S., Doğan, Z. (2017). Mechanisms of Alzheimer’s Disease pathogenesis and prevention: The brain, neural pathology, N-methyl-D-aspartate receptors, Tau protein and other risk factors. Clin. Psycho-pharmacol. Neurosci.,15 (1), 1–8.Search in Google Scholar

Kuwabara, M. (2016). Hyperuricemia, cardiovascular disease, and hypertension. Pulse, 3 (3–4), 242–252.Search in Google Scholar

Longo, F. M., Massa, S. M. (2004). Neuroprotective strategies in Alzheimer’s disease. NeuroRx, 1 (1), 117–127.Search in Google Scholar

Maiuolo, J., Oppedisano, F., Gratteri, S., Muscoli, C., Mollace, V. (2016). Regulation of uric acid metabolism and excretion. Int. J. Cardiol.,213, 8–14.Search in Google Scholar

Mattson, M. P. (2003). Excitotoxic and excitoprotective mechanisms: Abundant targets for the prevention and treatment of neurodegenerative disorders. NeuroMolecular Med., 3, 65–94.Search in Google Scholar

Mount, D. B., Sterns, R. H., Forman, J. P. (2020). Hypouricemia: Causes and clinical significance. UptoDate. https://www.uptodate.com/contents/hypouricemia-causes-and-clinical-significance (accessed 15 March 2021).Search in Google Scholar

Nakayama, A., Matsuo, H., Ohtahara, A., Ogino, K., Hakoda, M., Hamada, T., Hosoyamada, M., Yamaguchi, S., Hisatome, I., Shinomiya, N. (2019). Clinical practice guideline for renal hypouricemia (1st edition). Human Cell, 32 (2), 83–87.Search in Google Scholar

Olivares, D., Deshpande, V. K., Shi, Y., Lahiri, D. K., Greig, N. H., Rogers, J. T., Huang, X. (2012). N-Methyl D-Aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer’s Disease, vascular dementia and Parkinson’s Disease. Curr. Alzheimer Res.,9 (6), 746–758.Search in Google Scholar

Paganoni, S., Schwarzschild, M. A. (2016). Urate as a marker of risk and progression of neurodegenerative disease. Neurotherapeutics, 14 (1), 148–153.Search in Google Scholar

Pello, S., Boland, T., Dechant, V., Patel, S., Liang, T., Mandel, S. (2009). Uric acid’s relationship with stroke and Parkinson’s Disease: A review. Pract. Neurol.https://practicalneurology.com/articles/2009-july-aug/PN0809_07-php (accessed 15 March 2021).Search in Google Scholar

Perez-Gomez, M. V., Bartsch, L.-A., Castillo-Rodriguez, E., Fernandez-Prado, R., Kanbay, M., Ortiz, A. (2019). Potential dangers of serum urate-lowering therapy. Amer. J. Med.,132 (4), 457–467.Search in Google Scholar

Richette, P., Doherty, M., Pascual, E., Barskova, V., Becce, F., Castañeda-Sanabria, J., Coyfish, M., Guillo, S., Jansen, T. L., Janssens, H., et al. (2017). 2016 updated EULAR evidence-based recommendations for the management of gout. Ann. Rheum. Dis., 76 (1), 29–42.Search in Google Scholar

Saag, K. G., Fitz-Patrick, D., Kopicko, J., Fung, M., Bhakta, N., Adler, S., Storgard C., Baumgartner S., Becker, M. A. (2017). Lesinurad combined with allopurinol: A randomized, double-blind, placebo-controlled study in gout patients with an inadequate response to standard-of-care allopurinol (a US-based Study). Arthritis Rheumatol.,69 (1), 203–212.Search in Google Scholar

Sautner, J., Gruber, J., Herold, M., Zwerina, J., Leeb, B. F. (2013). Österreichische 3e-Empfehlungen zu Diagnose und Management von Gicht 2013. Wiener Klinische Wochenschrift,126 (3–4), 79–89 (in German).Search in Google Scholar

Sautin, Y. Y., Johnson, R. J. (2008). Uric acid: The oxidant-antioxidant paradox. Nucleosides Nucleotides Nucl. Acids,27 (6), 608–619.Search in Google Scholar

Settle, T. (2014). The role of uric acid as an antioxidant in selected neurodegenerative disease pathogenesis: A short review. Brain Disord. Ther.,03 (03). https://www.researchgate.net/publication/269980495_The_Role_of_Uric_Acid_as_an_Antioxidant_in_Selected_Neurodegenerative_Disease_Pathogenesis_A_Short_Review (accessed 15 March 2021).Search in Google Scholar

Singh, J. (2019). Gout and neurological disease. Is there a link? Annual American College of Rheumatology Convergence, 11 November 2020.Atlanta, GA, USA.Search in Google Scholar

Squadrito, G. L., Cueto, R., Splenser, A. E., Valavanidis, A., Zhang, H., Uppu, R. M., Pryor, W. A. (2000). Reaction of uric acid with peroxynitrite and implications for the mechanism of neuroprotection by uric acid. Arch. Biochem. Biophys., 376, 333–337.Search in Google Scholar

Son, C.-N., Kim, J.-M., Kim, S.-H., Cho, S.-K., Choi, C.-B., Sung, Y.-K., Kim T.-H., Bae S.-C., Yoo D.-H., Jun, J.-B. (2016). Prevalence and possible causes of hypouricemia at a tertiary care hospital. Korean J. Intern. Med.,31 (5), 971–976.Search in Google Scholar

Sundy, J. S., Baraf, H. S. B., Yood, R. A., Lawrwnce Edwards, N., Gutierrez-Urena, S. R., Treadwell, E. L., Vasquez-Mellado, J., White, W. B., Lipsky, P., Horowitz, Z., et al. (2011). Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: Two randomized controlled trials. JAMA,306 (7), 711–720.Search in Google Scholar

Tana, C., Ticinesi, A., Prati, B., Nouvenne, A., Meschi, T. (2018). Uric acid and cognitive function in older individuals. Nutrients, 10 (8), 975.Search in Google Scholar

Tausche, A.-K., Alten, R., Dalbeth, N., Kopicko, J., Fung, M., Adler, S., Bhakta N., Baumgartner S., Saag, K. (2017). Lesinurad monotherapy in gout patients intolerant to a xanthine oxidase inhibitor: A 6 month phase 3 clinical trial and extension study. Rheumatology, 56 (12), 2170–2178.Search in Google Scholar

Weinstein, J. R, Anderson, S. (2010). The aging kidney: Physiological changes. Advances Chron. Kidney Dis.,17 (4), 302–307.Search in Google Scholar

White, W. B., Saag, K. G., Becker, M. A., Borer, J. S., Gorelick, P. B., Whelton, A., Gunawardhana, L., CARES Investigators (2018). Cardiovas-cular safety of febuxostat or allopurinol in patients with gout. New Engl. J. Med.,378 (13), 1200–1210.Search in Google Scholar

Yu, K.-H., Chen, D.-Y., Chen, J.-H., Chen, S.-Y., Chen, S.-M., Cheng, T.-T., Hsieh, S.-C., Hsieh, T.-Y., Hsu, P.-F., Kuo, C.-F., et al. (2018). Management of gout and hyperuricemia: Multidisciplinary consensus in Taiwan. Int. J. Rheum. Dis.,21 (4), 772–787.Search in Google Scholar

Zhang, W., Iso, H., Murakami, Y., Miura, K., Nagai, M., Sugiyama, D., Ueshima H., Okamura, T. (2016). Serum uric acid and mortality form cardiovascular disease: EPOCH-JAPAN study. J. Atherosclerosis Thrombosis, 23 (6), 692–703.Search in Google Scholar

Recommended articles from Trend MD

Plan your remote conference with Sciendo